Fusion Pharmaceuticals Inc. (FUSN) Research

Fusion Pharmaceuticals Inc. is a clinical-stage oncology enterprise focused on creating precise radiopharmaceutical therapies. The company utilizes its groundbreaking Targeted Alpha Therapies platform, which incorporates its exclusive Fast-Clear linker technology. This innovative system enables the attachment of alpha particle-emitting isotopes to diverse targeting molecules, facilitating the targeted delivery of these potent payloads directly to cancerous growths. Its leading investigational compound, FPI-1434, is currently progressing through Phase 1 clinical trials as a singular treatment for individuals suffering from solid tumors that express the insulin-like growth factor 1 receptor. Beyond this, Fusion is conducting preclinical research into FPI-1434's effectiveness in conjunction with existing checkpoint inhibitors and DNA damage response inhibitors. These studies aim to thoroughly evaluate its anti-tumor effects, ideal dosage regimens, and pharmacological interactions within combination therapies. Furthermore, the firm is moving its earlier-stage candidate, FPI-1966, into clinical evaluation for the management of head and neck, and bladder cancers exhibiting fibroblast growth factor receptor. Fusion Pharmaceuticals also maintains a strategic partnership with AstraZeneca UK Limited, collaborating on the identification, advancement, and market introduction of alpha-emitting radiopharmaceuticals and combined cancer treatments. The company, established in 2014, is headquartered in Hamilton, Canada.

Open Fusion Pharmaceuticals Inc. (FUSN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.